J&J Expects Financial Ripple Effect From McNeil OTC Recall
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson expects the recall of pediatric liquid OTCs, including Tylenol and Motrin products, to diminish the firm's overall margins in addition to temporarily halting sales of some of its highest margin consumer products
You may also be interested in...
Silenor Deal Gives P&G Easy Access To Rx Market, Possible OTC Sales
Procter & Gamble's license to market the insomnia drug Silenor lets the firm re-enter the Rx drug market without development costs and opens the door to a potential OTC switch
J&J Quality Issues, Hill Concerns Spill Over To Blacksmith's PediaCare
The impact of McNeil Consumer Healthcare's quality control lapses extends to Blacksmith Brands, which becomes a congressional inquiry target after recalling PediaCare products manufactured at one of the Johnson & Johnson subsidiary's plants
Recall Stifles J&J's Consumer Product Sales Growth
A recall of Motrin, Tylenol and other OTC products linked to contaminated shipping pallets dashed Johnson & Johnson's expectations for launches and line extensions to drive consumer business sales growth in its most recent quarter